Drug Profile

Research programme: cancer therapeutic vaccines - Imunon

Latest Information Update: 18 Jun 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Imunon
Class Antineoplastics; Cancer vaccines; DNA vaccines; Immunotherapies
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Cancer

Most Recent Events

05 Apr 2024 Preclinical trials in Cancer in USA (IM) prior to April 2024
05 Apr 2024 Pharmacodynamics data from a preclinical study in Cancer presented at the 115^th Annual Meeting of the American Association for Cancer Research (AACR-2024)
09 Jan 2023 Celsion files for a provisional patent for a novel DNA-based vaccine, using the PLACCINE DNA vaccine technology platform

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com